A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 9000
Summary
- Conditions
- COVID-19
- SARS CoV-2 Infection
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 84 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04583995
- Collaborators
- Not Provided
- Investigators
- Study Director: Seth Toback, MD Novavax, Inc. Principal Investigator: Paul T Heath, MB BS FRACP FRCPCH Vaccine Institute, St Georges, University of London